US OptionsDetailed Quotes
GERN240705P5000
- 0.75
- 0.000.00%
15min DelayTrading Jul 2 10:14 ET
0.00High0.00Low
0.00Open0.75Pre Close0 Volume80 Open Interest5.00Strike Price0.00Turnover1609.65%IV1.46%PremiumJul 5, 2024Expiry Date0.69Intrinsic Value100Multiplier2DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.2787Delta0.0561Gamma1.61Leverage Ratio-0.4514Theta-0.0003Rho-0.45Eff Leverage0.0012Vega
Geron Stock Discussion
折扣价赶快买！
On June 2, 2024, Barclays initiated coverage of Geron Corporation (NasdaqGS:GERN) with an Overweight rating, setting a price target of $9. At the time of this announcement, Geron’s stock was trading at $4.83, indicating a bullish sentiment from Barclays and predicting significant potential upside for investors. $Geron(GERN.US)$
https://stockregion.app/p/investment-bank-initiates-overweight
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US)$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US)$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US)$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
This could get interesting considering the short stats.
2.85 days to cover. 10.46% short floats.
On June 7, 2024, Geron Corporation, a commercial-stage biopharmaceutical company, proudly announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), marking a milestone in the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This ...
No comment yet